Also

Biogen Idec Inc. said it would buy closely held Conforma Therapeutics Corp. of San Diego for as much as $250 million. Conforma would bring Biogen two experimental cancer compounds in the earliest stage of human tests. The deal is expected to be completed in the second quarter.